Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2024-02-29 00:00:00 ET · period of report 2024-02-27 · accession 0001415889-24-005930 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-29 | 2024-02-27 | ELVN | Hohl Benjamin | CFO | S - Sale+OE | $16.97 | -3,250 | 0 | -100% | -$55.2K |
| D | 2024-02-29 | 2024-02-27 | ELVN | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,250 | 3,250 | New | +$8,060 |
| D | 2024-02-29 | 2024-02-27 | ELVN | Hohl Benjamin | CFO | M - OptEx | $0.00 | -3,250 | 242.6K | -1% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-27 | S | D | 3,250 | $16.97 | 0 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $16.60 to $17.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Common Stock | 2024-02-27 | M | A | 3,250 | $2.48 | 3,250 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2024-02-27 | M | D | 3,250 | $0.00 | 242,620 | D | $2.48 · — to 2031-08-02 | 3,250 Common Stock | (F3) The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. |